FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Forsyth

Research Profile

Disorders

Procedures

Living Beings

Concepts & Ideas

Anatomy

Chemicals & Drugs

Thiotepa

Co-author Network

Publications

TOP 3
Don G Morris; Alexander H Paterson; Matthew C Coffey; Lisa M DiFrancesco; Xiaolan Feng; Kevin Fonseca; Peter A Forsyth; Brad Thompson
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Craig N Jenne; Peter A Forsyth; Braedon McDonald; Grant McFadden; Masmudur M Rahman; Connie H Y Wong; Franz J Zemp; Paul Kubes
Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps.
Henry Ogbomo; Christopher H Mody; Jindrich Cinatl; Peter A Forsyth
Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Forsyth (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Don G Morris; Alexander H Paterson; Matthew C Coffey; Lisa M DiFrancesco; Xiaolan Feng; Kevin Fonseca; Peter A Forsyth; Brad Thompson
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):696-706.
2013: Craig N Jenne; Peter A Forsyth; Braedon McDonald; Grant McFadden; Masmudur M Rahman; Connie H Y Wong; Franz J Zemp; Paul Kubes
Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps.
Cell host & microbe 2013;13(2):169-80.
2011: Henry Ogbomo; Christopher H Mody; Jindrich Cinatl; Peter A Forsyth
Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
Trends in molecular medicine 2011;17(8):433-41.
2011: Manbok Kim; K A Garant; Nicole I zur Nieden; Tommy Alain; S D Loken; Stefan J Urbanski; Peter A Forsyth; Derrick E Rancourt; P W K Lee; Randal Johnston
Attenuated reovirus displays oncolysis with reduced host toxicity.
British journal of cancer 2011;104(2):290-9.
2010: Xueqing Lun; Jennifer Chan; Hongyuan Zhou; Beichen Sun; John J P Kelly; Owen Owen Stechishin; John C Bell; Kelley A Parato; Kang Hu; Dominique Vaillant; Jiahu Wang; Ta-Chiang Liu; Caroline Breitbach; David Kirn; Donna L Senger; Peter A Forsyth
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(11):1927-36.
2010: Barbara Blasiak; Boguslaw Tomanek; Abedelnasser Abulrob; Umar Iqbal; Danica Stanimirovic; Homam Albaghdadi; Tadeusz Foniok; Xueqing Lun; Peter A Forsyth; Garnette R Sutherland
Detection of T(2) changes in an early mouse brain tumor.
Magnetic resonance imaging 2010;28(6):784-9.
2010: Franz J Zemp; Juan Carlos Corredor; Xueqing Lun; Daniel A Muruve; Peter A Forsyth
Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.
Cytokine & growth factor reviews 2010;21(2-3):103-17.
2010: Chandini M Thirukkumaran; Michael J Nodwell; Kensuke Hirasawa; Zhong Qiao Shi; Roman Diaz; Joanne Luider; Randal N Johnston; Peter A Forsyth; anthony magliocco; Patrick Lee; Sandra Nishikawa; Bryan Donnelly; Matt Coffey; Kiril Trpkov; Kevin Fonseca; Jason Spurrell; Don G Morris
Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Cancer research 2010;70(6):2435-44.
2010: Shelly Lwu; Mark G Hamilton; Peter A Forsyth; J Gregory Cairncross; Ian F Parney
Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience.
Journal of neuro-oncology 2010;96(3):403-8.
2010: Xueqing Lun; Tommy Alain; Franz J Zemp; Hongyuan Zhou; Masmudur M Rahman; Mark G Hamilton; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Cancer research 2010;70(2):598-608.
2009: Gloria B Roldán; James N Scott; John B McIntyre; Marisa Dharmawardene; Paula A de Robles; anthony magliocco; Elizabeth S Y Yan; Ian F Parney; Peter A Forsyth; J Gregory Cairncross; Mark G Hamilton; Jay Easaw
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2009;36(5):617-22.
2009: John J P Kelly; Owen Stechishin; Andrew Chojnacki; Xueqing Lun; Beichen Sun; Donna L Senger; Peter A Forsyth; Roland N Auer; Jeff F Dunn; J Gregory Cairncross; Ian F Parney; Samuel Weiss
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Stem cells (Dayton, Ohio) 2009;27(8):1722-33.
2009: Xue Qing Lun; Ji-Hyun Jang; Nan Tang; Helen Deng; Renee Head; John C Bell; David F Stojdl; Catherine L Nutt; Donna L Senger; Peter A Forsyth; J Andrea McCart
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(8):2777-88.
2008: Paula de Robles; John McIntyre; Sanjog Kalra; Gloria Roldán; Gregory Cairncross; Peter A Forsyth; anthony magliocco; Mark Hamilton; Jacob Easaw
Methylation status of MGMT gene promoter in meningiomas.
Cancer genetics and cytogenetics 2008;187(1):25-7.
2008: Nimish A Mohile; Peter A Forsyth; Douglas Stewart; Jeffrey J Raizer; Nina Paleologos; Tarun Kewalramani; David N Louis; J Gregory Cairncross; Lauren E Abrey
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Journal of neuro-oncology 2008;89(2):187-93.
2008: Angelique E Sijben; John B McIntyre; Gloria B Roldán; Jacob C Easaw; Elizabeth Yan; Peter A Forsyth; Ian F Parney; anthony magliocco; Hans J J A Bernsen; J Gregory Cairncross
Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.
Journal of neuro-oncology 2008;89(1):97-103.
2008: Gloria Roldán; P M A Brasher; Giacomo G Vecil; Donna L Senger; Barry Rewcastle; Gregory Cairncross; Peter A Forsyth; Mark Hamilton
Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2008;35(2):210-5.
2008: Gloria Roldán; James Scott; David George; Ian F Parney; Jay Easaw; Gregory Cairncross; Peter A Forsyth; Elizabeth Yan
Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2008;35(2):204-9.
2008: Robert Brown; Magdalena Zlatescu; Angelique Sijben; Gloria Roldan; Jay Easaw; Peter A Forsyth; Ian Parney; Robert Sevick; Elizabeth Yan; Douglas Demetrick; David Schiff; Gregory Cairncross; Ross Mitchell
The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2357-62.
2008: Peter A Forsyth; Gloria Roldán; David George; Carla Wallace; Cheryl Ann Palmer; Don Morris; Gregory Cairncross; Maureen Vallee Matthews; James Markert; Yancey Gillespie; Matt Coffey; Brad Thompson; Mark Hamilton
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(3):627-32.
2008: Yushui Wu; Xueqing Lun; Hongyuan Zhou; Limei Wang; Beichen Sun; John C Bell; John W Barrett; Grant McFadden; Jaclyn A Biegel; Donna L Senger; Peter A Forsyth
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1218-27.
2007: John W Barrett; Lindsay R Alston; Fuan Wang; Marianne M Stanford; Philippe-Alexandre Gilbert; Xiujuan Gao; June Jimenez; Danielle Villeneuve; Peter A Forsyth; Grant McFadden
Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.
Journal of neurovirology 2007;13(6):549-60.
2007: Tommy Alain; Josée F Wong; R Endersby; Stefan J Urbanski; Patrick W K Lee; Daniel A Muruve; Randal Johnston; Peter A Forsyth; Paul L Beck
Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model.
Cancer gene therapy 2007;14(10):867-72.
2007: Xueqing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
Cancer research 2007;67(18):8818-27.
2007: Murielle E L Mauer; Roger Stupp; Martin J B Taphoorn; Corneel Coens; David Osoba; Christine Marosi; R Wong; O de Witte; J G Cairncross; Fabio Efficace; René-Olivier Mirimanoff; Peter A Forsyth; Martin J van den Bent; M Weller; andrew bottomley
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.
British journal of cancer 2007;97(3):302-7.
2007: Angela L M Johnston; Xueqing Lun; Jennifer J Rahn; Abdelhamid Liacini; Limei Wang; Mark G Hamilton; Ian F Parney; Barbara L Hempstead; Stephen M Robbins; Peter A Forsyth; Donna L Senger
The p75 neurotrophin receptor is a central regulator of glioma invasion.
PLoS biology 2007;5(8):e212.
2007: Tommy Alain; Tom Sy Kim; Xueqing Lun; Abdelhamid Liacini; Leslie A Schiff; Donna L Senger; Peter A Forsyth
Proteolytic disassembly is a critical determinant for reovirus oncolysis.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(8):1512-21.
2007: Manbok Kim; C Egan; Tommy Alain; Stefan J Urbanski; Patrick W K Lee; Peter A Forsyth; Randal Johnston
Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells.
Oncogene 2007;26(28):4124-34.
2007: Anthony T Power; Jiahu Wang; Theresa J Falls; Jennifer M Paterson; Kelley A Parato; Brian Lichty; David F Stojdl; Peter A Forsyth; Harold Atkins; John C Bell
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(1):123-30.
2006: Xueqing Lun; Donna L Senger; Tommy Alain; Andra Oprea; Kelley A Parato; David F Stojdl; Brian Lichty; Anthony T Power; Randal Johnston; Mark Hamilton; Ian F Parney; John C Bell; Peter A Forsyth
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Journal of the National Cancer Institute 2006;98(21):1546-57.
2006: Tommy Alain; Manbok Kim; Randal Johnston; Stefan J Urbanski; Anna E Kossakowska; Peter A Forsyth; Patrick W K Lee
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
British journal of cancer 2006;95(8):1020-7.
2006: P Tang; G Roldan; P M A Brasher; Dorcas Fulton; Wilson Roa; AD Murtha; J Gregory Cairncross; Peter A Forsyth
A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Journal of neuro-oncology 2006;78(3):311-6.
2006: Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan Lester Finlay; Sharon L Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter A Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsay; Stephen D Nimer; Lisa De Angelis; J Gregory Cairncross
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
Neuro-oncology 2006;8(2):183-8.
2006: Erin L Moss; J Steven A Simpson; Guy Pelletier; Peter A Forsyth
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Psycho-oncology 2006;15(3):259-67.
2005: Martin J B Taphoorn; Roger Stupp; Corneel Coens; David Osoba; Rolf-Dieter Kortmann; Martin J van den Bent; Warren Mason; René-Olivier Mirimanoff; Brigitta Baumert; Elizabeth Eisenhauer; Peter A Forsyth; andrew bottomley
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
The lancet oncology 2005;6(12):937-44.
2005: Kelley A Parato; Donna L Senger; Peter A Forsyth; John C Bell
Recent progress in the battle between oncolytic viruses and tumours.
Nature reviews. Cancer 2005;5(12):965-76.
2005: Yan Zhou; Jing Zhang; Qiang Liu; Robert Bell; Daniel A Muruve; Peter A Forsyth; Mayi Arcellana-Panlilio; Stephen Robbins; V Wee Yong
The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells.
Carcinogenesis 2005;26(12):2058-68.
2005: Xueqing Lun; Wenqing Yang; Tommy Alain; Zhong Qiao Shi; Huong Muzik; John W Barrett; Grant McFadden; John Bell; Mark G Hamilton; Donna L Senger; Peter A Forsyth
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Cancer research 2005;65(21):9982-90.
2005: Chandini M Thirukkumaran; Joanne M Luider; Douglas A Stewart; Tommy Alain; James A Russell; Iwona A Auer; Peter A Forsyth; Donald G Morris
Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts.
Bone marrow transplantation 2005;35(11):1055-64.
2005: Sarah Kirby; Stan Z Gertler; Warren Mason; Christopher Watling; Peter A Forsyth; Jacinta Aniagolu; Robert Stagg; Matthew Wright; Jean Powers; Elizabeth A Eisenhauer
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group.
Neuro-oncology 2005;7(2):183-8.
2004: Wen Qing Yang; Xueqing Lun; Cheryl Ann Palmer; M Elizabeth Wilcox; Huong Muzik; Zhong Qiao Shi; Richard H Dyck; Matt Coffey; Brad Thompson; Mark Hamilton; Sandra G Nishikawa; P M A Brasher; Kevin Fonseca; David George; N Barry Rewcastle; Randal Johnston; Doug Stewart; Patrick W K Lee; Donna L Senger; Peter A Forsyth
Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8561-76.
2004: Wen Qing Yang; Donna L Senger; Xueqing Lun; Huong Muzik; Zhong Qiao Shi; Richard H Dyck; Kara L Norman; P M A Brasher; N Barry Rewcastle; David George; Doug Stewart; Patrick W K Lee; Peter A Forsyth
Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.
Gene therapy 2004;11(21):1579-89.
2004: Joseph F Megyesi; Edward Kachur; Donald H Lee; Magdalena C Zlatescu; Rebecca A Betensky; Peter A Forsyth; Yoshifumi Okada; Hikaru Sasaki; Masahiro Mizoguchi; David N Louis; J Gregory Cairncross
Imaging correlates of molecular signatures in oligodendrogliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4303-6.
2004: Wilson Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; Dorcas Fulton; Sunil Gulavita; Chunhai Hao; S Husain; AD Murtha; Kenneth C Petruk; Doug Stewart; P Tai; R Urtasun; J Gregory Cairncross; Peter A Forsyth
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1583-8.
2004: Kenneth B Fallon; Cheryl Ann Palmer; Kevin A Roth; L Burt Nabors; Wenquan Wang; Mark Carpenter; Ruma Banerjee; Peter A Forsyth; Keith Rich; Arie Perry
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
Journal of neuropathology and experimental neurology 2004;63(4):314-22.
2003: Diego Vieyra; Donna L Senger; Tatsuya Toyama; Huong Muzik; P M A Brasher; Randal Johnston; Karl Riabowol; Peter A Forsyth; Tatsuya Toyam
Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5952-61.
2003: Lauren E Abrey; Craig Moskowitz; Warren P Mason; Michael Crump; Douglas Stewart; Peter A Forsyth; Nina Paleologos; Denise D Correa; Nicole D Anderson; Dawn Caron; Andrew D Zelenetz; Stephen D Nimer; Lisa De Angelis
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4151-6.
2003: Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan Lester Finlay; Sharon L Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter A Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsey; Stephen D Nimer; Lisa De Angelis; J Gregory Cairncross
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Journal of neuro-oncology 2003;65(2):127-34.
2003: Karl Bélanger; David MacDonald; Gregory Cairncross; Stan Gertler; Peter A Forsyth; Susan Burdette-Radoux; Julie Bergeron; Denis Soulières; Samuel Ludwin; Nancy Wainman; Elizabeth Eisenhauer
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.
Investigational new drugs 2003;21(4):473-80.
2003: Wen Qing Yang; Donna L Senger; Huong Muzik; Zhong Qiao Shi; Denise Johnson; P M A Brasher; N Barry Rewcastle; Mark Hamilton; Jim Rutka; Johannes Wolff; Cynthia Wetmore; Tom Curran; Patrick W K Lee; Peter A Forsyth
Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
Cancer research 2003;63(12):3162-72.
2003: Donna L Senger; J Gregory Cairncross; Peter A Forsyth
Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?
Cancer journal (Sudbury, Mass.) 2003;9(3):214-21.
2003: Peter A Forsyth; Susan Weaver; Dorcas Fulton; P M A Brasher; Garnette Sutherland; Doug Stewart; Neil A Hagen; Penny Barnes; J Gregory Cairncross; Lisa De Angelis
Prophylactic anticonvulsants in patients with brain tumour.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2003;30(2):106-12.
2003: T Cheng; Peter A Forsyth; Ahsan Chaudhry; Donald Morris; Stefan Gluck; James A Russell; Douglas A Stewart
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Bone marrow transplantation 2003;31(8):679-85.
2003: Robert K Nuttall; Caroline J Pennington; Jennifer Taplin; Alison Wheal; V Wee Yong; Peter A Forsyth; Dylan R Edwards
Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells.
Molecular cancer research : MCR 2003;1(5):333-45.
2002: M I Zia; Peter A Forsyth; Ahsan Chaudhry; J Russell; Douglas A Stewart
Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma.
Bone marrow transplantation 2002;30(9):565-9.
2002: James N Scott; P M A Brasher; Robert J Sevick; N Barry Rewcastle; Peter A Forsyth
How often are nonenhancing supratentorial gliomas malignant? A population study.
Neurology 2002;59(6):947-9.
2001: L L Groft; Huong Muzik; N Barry Rewcastle; Randal Johnston; Vera Knäuper; Marc A Lafleur; Peter A Forsyth; Dylan R Edwards
Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.
British journal of cancer 2001;85(1):55-63.
2001: M Elizabeth Wilcox; W Yang; Donna L Senger; N Barry Rewcastle; Donald G Morris; P M A Brasher; Zhong Qiao Shi; Randal Johnston; Sandra G Nishikawa; Patrick W K Lee; Peter A Forsyth
Reovirus as an oncolytic agent against experimental human malignant gliomas.
Journal of the National Cancer Institute 2001;93(12):903-12.
2001: Marc A Lafleur; Peter A Forsyth; Susan J Atkinson; Gillian Murphy; Dylan R Edwards
Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity.
Biochemical and biophysical research communications 2001;282(2):463-73.
2001: H Wong; Huong Muzik; L L Groft; Marc A Lafleur; C Matouk; Peter A Forsyth; G A Schultz; S J Wall; Dylan R Edwards
Monitoring MMP and TIMP mRNA expression by RT-PCR.
Methods in molecular biology (Clifton, N.J.) 2001;151():305-20.
2000: S A Raithatha; Huong Muzik; H Muzik; N Barry Rewcastle; Randal Johnston; Dylan R Edwards; Peter A Forsyth
Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas.
Neuro-oncology 2000;2(3):145-50.
2000: Gregory Cairncross; Lode Swinnen; Robert Bayer; Steven Rosenfeld; Donna Salzman; Nina Paleologos; Lynne Kaminer; Peter A Forsyth; Douglas Stewart; Kendra Peterson; Wendy Hu; David MacDonald; D Ramsay; Alan Smith
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Neuro-oncology 2000;2(2):114-9.
2000: Stan Gertler; D MacDonald; M Goodyear; Peter A Forsyth; David J Stewart; K Belanger; J Perry; D Fulton; W Steward; Nancy Wainman; Lesley Seymour
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):315-8.
1999: Tatsuya Toyama; H Iwase; P Watson; Huong Muzik; E Saettler; anthony magliocco; Lisa M DiFrancesco; Peter A Forsyth; Igor Garkavtsev; S Kobayashi; Karl Riabowol
Suppression of ING1 expression in sporadic breast cancer.
Oncogene 1999;18(37):5187-93.
1999: James N Scott; N Barry Rewcastle; P M A Brasher; Dorcas Fulton; J A MacKinnon; Mark Hamilton; J Gregory Cairncross; Peter A Forsyth
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.
Annals of neurology 1999;46(2):183-8.
1999: A Price; Q Shi; D Morris; M Elizabeth Wilcox; P M A Brasher; N Barry Rewcastle; DR Shalinsky; H Zou; Krzysztof Appelt; Randal Johnston; V Wee Yong; D Edwards; Peter A Forsyth
Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):845-54.
1999: Peter A Forsyth; H Wong; T D Laing; N Barry Rewcastle; Donald G Morris; Huong Muzik; K J Leco; Randal Johnston; P M A Brasher; Garnette R Sutherland; Dylan R Edwards
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
British journal of cancer 1999;79(11-12):1828-35.
1999: P Frölichsthal-Schoeller; Angelo L Vescovi; CA Krekoski; G Murphy; Dylan R Edwards; Peter A Forsyth
Expression and modulation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinases in human embryonic CNS stem cells.
Neuroreport 1999;10(2):345-51.
1999: Marja J Verhoef; Neil A Hagen; G Pelletier; Peter A Forsyth
Alternative therapy use in neurologic diseases: use in brain tumor patients.
Neurology 1999;52(3):617-22.
1999: D Hao; Lisa M DiFrancesco; P M A Brasher; C deMetz; D S Fulton; Lisa De Angelis; Peter A Forsyth
Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):65-70.
1998: Matthew C Coffey; James E Strong; Peter A Forsyth; Patrick W K Lee
Reovirus therapy of tumors with activated Ras pathway.
Science (New York, N.Y.) 1998;282(5392):1332-4.
1998: James N Scott; N Barry Rewcastle; P M A Brasher; Dorcas Fulton; Neil A Hagen; J A MacKinnon; Garnette R Sutherland; J Gregory Cairncross; Peter A Forsyth
Long-term glioblastoma multiforme survivors: a population-based study.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1998;25(3):197-201.
1998: V Wee Yong; CA Krekoski; Peter A Forsyth; R Bell; Dylan R Edwards
Matrix metalloproteinases and diseases of the CNS.
Trends in neurosciences 1998;21(2):75-80.
1998: Peter A Forsyth; T D Laing; A W Gibson; N Barry Rewcastle; P M A Brasher; Garnette R Sutherland; Randal Johnston; Dylan R Edwards
High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma.
Journal of neuro-oncology 1998;36(1):21-9.
1997: Peter A Forsyth; Casilda Balmaceda; Kendra Peterson; Andrew D Seidman; P M A Brasher; Lisa De Angelis
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Journal of neuro-oncology 1997;35(1):47-53.
1997: LuZhuang Gao; Lieqi Liu; D van Meyel; Gregory Cairncross; Peter A Forsyth; D Kimmel; R B Jenkins; Norman Lassam; David Hogg
Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):977-81.
1997: Peter A Forsyth; Josep Dalmau; Francesc Graus; V Cwik; Marc K Rosenblum; Jerome B Posner
Motor neuron syndromes in cancer patients.
Annals of neurology 1997;41(6):722-30.
1997: Peter A Forsyth; E Petrov; Houman Mahallati; J Gregory Cairncross; P M A Brasher; M Elizabeth MacRae; Neil A Hagen; P Barnes; Robert J Sevick
Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2076-81.
1996: Peter A Forsyth; Lisa De Angelis
Biology and management of AIDS-associated primary CNS lymphomas.
Hematology/oncology clinics of North America 1996;10(5):1125-34.
1996: S Meckling; O Dold; Peter A Forsyth; P M A Brasher; Neil A Hagen
Malignant supratentorial glioma in the elderly: is radiotherapy useful?
Neurology 1996;47(4):901-5.
1996: Peter A Forsyth; J Gregory Cairncross
Chemotherapy for malignant gliomas.
Baillière's clinical neurology 1996;5(2):371-93.
1996: David MacDonald; Gregory Cairncross; D Stewart; Peter A Forsyth; C Sawka; N Wainman; Elizabeth Eisenhauer
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):205-7.
1996: Dorcas Fulton; R Urtasun; Peter A Forsyth
Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
Journal of neuro-oncology 1996;27(2):149-55.
1996: Peter A Forsyth; Gregory Cairncross; D Stewart; M Goodyear; N Wainman; Elizabeth Eisenhauer
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Investigational new drugs 1996;14(2):203-6.
1995: Peter A Forsyth; J Gregory Cairncross
Treatment of malignant glioma in adults.
Current opinion in neurology 1995;8(6):414-8.
1994: Peter A Forsyth; Joachim Yahalom; Lisa De Angelis
Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS.
Neurology 1994;44(8):1473-9.
1994: K Peterson; Peter A Forsyth; Jerome B Posner
Paraneoplastic sensorimotor neuropathy associated with breast cancer.
Journal of neuro-oncology 1994;21(2):159-70.
1993: Peter A Forsyth; Jerome B Posner
Headaches in patients with brain tumors: a study of 111 patients.
Neurology 1993;43(9):1678-83.